AbbVie (ABBV) Tops Q2 EPS by 3c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
William Blair Remains Bullish on AbbVie (ABBV) Following 2Q Beat
July 30, 2018 8:45 AM EDTWilliam Blair reiterated an Outperform rating and $127.00 price target on Abbvie (NYSE: ABBV) following the company's 2Q earnings report. Revenues for the quarter were $8.3 billion, beating consensus of $8.2 billion. Non-GAAP EPS were $2.00, above consensus of $1.97.
Management issued updated guidance for 2018 non-GAAP EPS of $7.76 to $7.86... More
Abbvie (ABBV) PT Lowered to $110 at Cowen
July 27, 2018 11:57 AM EDTCowen lowered its price target on Abbvie (NYSE: ABBV) to $110.00 (from $130.00) while maintaining an Outperform rating following beat and raise.
The firm is lowering the target based on a reduced target PE of 14x 2018 EPS (prior 17x) given lingering uncertainties (legal, pricing,... More
